According to CNBC, private equity firm DigitalBridge surged over 32% premarket on reports Japan’s SoftBank is in advanced talks to acquire it, with a deal potentially announced as soon as Monday. Nvidia fell about 1% after it reportedly bought AI chip startup Groq’s assets for around $20 billion, its largest deal ever, following a 1% gain on Friday. Meanwhile, Praxis Precision Medicines shares gained more than 2% after BTIG named it a top pick for 2026 and hiked its price target to $843 from $507, implying over 213% upside. Finally, South Korean online retailer Coupang advanced over 2% after offering customers affected by a data breach shopping vouchers worth KRW 1.685 trillion ($1.17 billion), with founder Kim Bom apologizing over the weekend.
Stakeholder Whiplash
So, what does all this frantic pre-market action actually mean for the people involved? Let’s start with the potential SoftBank-DigitalBridge deal. If it goes through, it’s a massive validation for the data center and digital infrastructure space. We’re talking about a major liquidity event for DigitalBridge’s investors and a huge strategic bet by SoftBank. But here’s the thing: a 32% pop on a rumor is wild. It shows just how hungry the market is for any sign of consolidation and growth in the AI-adjacent physical asset world. For the sector, it probably means even more capital chasing these types of deals.
The Nvidia Machine Keeps Rolling
Nvidia’s reported $20 billion grab for Groq’s assets is fascinating. On one hand, a 1% dip after such news is basically noise for a stock that moves like Nvidia. It’s more about digesting the size than questioning the logic. This isn’t just an acquisition; it’s an assimilation. Nvidia isn’t just buying a competitor—it’s absorbing talent and IP to further cement its dominance. For developers and enterprises betting on Nvidia’s ecosystem, it’s a sign the company will spend whatever it takes to stay on top. For competitors? Well, it’s another reminder of the sheer financial firepower they’re up against. Can anyone even play in this league anymore?
Biotech Bets and Consumer Make-Goods
The Praxis and Coupang stories are totally different but just as telling. BTIG’s price target for Praxis is beyond bullish—it’s galactic. A call for 213% upside in a clinical-stage biotech is the ultimate high-conviction, high-risk bet. It moves the stock now, but the real impact is on future fundraising and partnership discussions. It’s a huge credibility boost. As for Coupang, a $1.17 billion voucher program for a data breach is a staggering cost. It immediately hits the bottom line, but the 2% gain suggests the market sees it as a necessary cost to maintain trust in a competitive retail market. It’s a painful but probably smart long-term play to keep users from fleeing. Basically, they’re buying back their reputation.
